Inhibitors of purine nucleoside phosphorylase may have therapeutic value in the treatment of T-cell proliferative diseases such as T-cell leukemia, in the suppression of host-versus-graft response in organ transplants, and in the treatment of T-cell-mediated autoimmune diseases. Competitive inhibitors of this enzyme have been designed using the three-dimensional structure of the enzyme determined by X-ray crystallography. This approach has resulted in the synthesis of the most potent and membrane-permeable inhibitors of purine nucleoside phosphorylase reported so far.
Introduction
The search for new chemical entities is the cornerstone of the drug discovery process. Most drugs that are in use today were discovered more or less empirically. The two prevailing methods of drug discovery are the 'screening method' and 'rational' drug design. Most pharmaceutical companies today employ some form of rational drug-design methodology although screening is also routinely practiced. Besides being random, screening is inherently repetitious and time consuming. Even lead optimization by means of structural modifications to an active compound is primarily a trial-and-error process, even though the probability of success is much greater than a purely random process. A number of different approaches have been developed to make this approach more efficient.
Recent advances in biotechnology, macromolecular crystallography, computer graphics and related fields have led to a new approach in drug discovery called structure-based drug design. Structure-based drug design is the discovery of drugs based on a detailed structural knowledge of the target (enzyme or receptor) and the interaction of small molecules with it. Clearly, structural information in combination with graphical methods for displaying accessible volume, electrostatic potential and hydrophobicity of the active site of the target macromolecule greatly facilitates the drug-design process. Further enhancement in the quality of the 'designed compounds' is expected from methods that can accurately evaluate the target molecule in terms of binding conformation, binding affinity and bindinginduced conformational changes in the protein. Accurate prediction of binding affinities and protein conformational changes are currently not routinely possible although significant advances are being made.
The foundation of structure-based drug design is the detailed information about the three-dimensional molecular structure of the target macromolecule e.g. enzymes and receptors. Fig. 1 outlines the overall strategy of this approach. At the present time, X-ray crystallography is the preferred technique for obtaining the atomic resolution structural data that would usually be required for drug design. Recently, we at BioCryst have successfully completed a project to design and synthesize potent inhibitors of the enzyme purine nucleoside phosphorylase (PNP) using the three-dimensional structure of the active site of the enzyme (Ealick et al., 1991) . The application of structured-based drug design in this project is the subject of this article.
Purine nucleoside phosphorylase (PNP, E.C. 2.4.2.1) catalyzes the reversible phosphorylysis of ribonucleosides and 2'-deoxyribonucleosides of guanine, hypoxanthine and a number of related nucleoside analogs (Parks & Agarwal, 1972) . Although under equilibrium conditions the isolated enzyme catalyzes the nucleoside synthesis, it normally acts in the phosphorolytic direction in intact cells.
Interest in PNP as a drug target arises from its ability to rapidly metabolize purine nucleosides and from its role in the T-cell branch of the immune system. The high level of PNP activity in vivo suggests that the chemotherapeutic potential of certain purine nucleoside analogs may be severely compromised by PNP metabolism. These include the potential anticancer agent 2'-deoxy-6-thioguanosine (LePage, Junga & Bowman, 1964) , and the anti-AIDS drug 2',3'-dideoxyinosine (Erion, 1990) . Hence, a combination of a PNP inhibitor and these purine-nucleoside analogs may prove to be more efficacious. PNP inhibitors by themselves have potential therapeutic value based on the finding that patients lacking PNP activity exhibit severe T-cell immunodeficiency while maintaining normal or exaggerated B-cell function. This profile suggests that PNP inhibitors might be useful in the treatment of T-cell proliferative diseases such as T-cell leukemia or T-cell lymphoma, in the suppression of the host-versus-graft response in organ transplant patients, and in the treatment of T-cell mediated autoimmune diseases such as rheumatoid arthritis and lupus erythematosus (Ottemess & Bilven, 1989) . Despite the potential benefits of PNP inhibitors and despite the large number of PNP inhibitors The amino-acid residues that interact with guanine moiety are shown in red, hydrophobic pocket in blue and the phosphate-binding site is shown in green.
that have been synthesized to date, no compound has yet reached clinical trials. One problem is the potency of the membrane-permeable compounds thus far prepared. Although potencies for the best compounds have affinities 10-100 higher than the natural substrate (K m _~ 4 mM), it is expected that T-cell immunotoxicity will only occur with very tight binding inhibitors (K i, < 10 nM) due to the high in vivo PNP activity and competition with substrate. Hence, we determined the structure of human PNP by X-ray crystallography and have utilized these results in combination with computerassisted molecular modeling to design novel highly potent inhibitors of this key enzyme.
hydrophobic pocket serves to orient the sugar to facilitate nucleophilic attack by phosphate and subsequent inversion at C 1'. A 'swinging gate' consisting of residues 241-260 controls access to the active site ( Fig. 4 ). This gate,
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Glu 250 Experimental PNP has been isolated from both eukaryotic and prokaryotic cells (Stoeckler, 1984) and functions in the purine salvage pathway. Human PNP is a trimer of identical subunits with a total molecular weight of about 97000Da. Each subunit contains 289 amino-acid residues. Crystals of human PNP for X-ray diffraction studies were grown from ammonium sulfate solution as described previously (Cook, Ealick, Bugg, Stoeckler & Parks, 1981) . These crystals are stored in artificial mother liquor solution made up of 60% ammonium sulfate, 0.05 M citrate buffer at pH 5.4. The space group is R32 with hexagonal cell parameters a = 142.9 (1) and c = 165.2 (1)A. PNP crystals contain about 76% solvent and diffracts to around 2.8,~ resolution. The threedimensional structure was determined by multiple isomorphous replacement techniques using synchrotron radiation (Ealick et al., 1990) . The native and guanine 7 PNP complex structures have been ref'med to 2.8A resolution.
Structure description
The X-ray analysis confirmed the trimeric nature of the enzyme in which the subunits are related by the crystallographic threefold axis (Fig. 2) . Each subunit contains an eight-stranded/3-sheet and a five-stranded 13sheet which join to form a distorted/3-barrel. Seven o~helices surround this/3-sheet structure. The active site is located near the subunit-subunit boundary within the trimer, and involves seven polypeptide segments from one subunit and a short segment from the adjacent subunit. The purine-binding site is composed of residues Glu201, Lys244 and Asn243 which form hydrogen bonds with N1, 06 and N7 of purine (Fig. 3) . The remainder of the purine-binding pocket is largely hydrophobic, being composed of residues Alall6, Phe200 and Va1217. The phosphate-binding site is composed of residues Ser33, Arg84, His86 and Ser220 with the phosphate positioned for nucleophilic attack at C1 of the nucleoside. The sugar-binding site is mostly hydrophobic consisting of residues Tyr88, Phe159 (of the adjacent subunit), Phe200 and His257. This closed in the native enzyme, opens during substrate binding to accommodate the substrate or a substrate-like competitive inhibitor. The electron density for these residues in the native structure was poorly defined indicating high thermal motion for these residues. The maximum movement caused by substrate or inhibitor binding occurs at His257, which is displaced outwards by several ~ngstrbms. The gate is anchored near the central fl-sheet at one end and near the C-terminal helix at the other end. The gate movement is complex and appears to involve a helical transformation near residues 257-261. Consequently, initial inhibitor-modeling attempts using the native PNP structure were far less successful than subsequent analyses in which coordinates for the guanine-PNP complex were used. Because of the magnitude of the changes that occur during substrate binding, it is unlikely that modeling studies based on the native structure alone would have accurately predicted the structure of the complex between PNP and purine analog inhibitors.
Structure-based drug design
At the beginning of our studies several PNP inhibitors had been reported with K i values in the 10 -6 tO 10 -7 range including 8-aminoguanine (Stoeckler, Cambor, Kuhns, Chu & Parks, 1982) , 9-benzyl-8-aminoguanine (Shewach, Chen, Pillote, Townsend & Daddona, 1986) , and 5'-iodo-9-deazainosine (Stoeckler et al., 1986) . Acyclovir diphosphate had been shown to have a K i near l0 -s if assayed at 1 mM phosphate rather than the more frequently used value of 50mM (Tuttle & Krenitsky, 1984) . During our studies, the synthesis of 8-amino-9-(2-thienylmethyl)guanine was reported with a K i of 6.7 × 10 -8 M (Gilbertsen et al., 1987) . In order to understand the interaction of these inhibitors with the active-site residues, these compounds were obtained and crystallographic analyses were carried out. The most important findings were the following: (1) 8-amino substituents enhance binding by forming hydrogen bonds with Thr242 and possibly the carbonyl O atom of Alall6;
(2) 9-deaza analogs acquire potency through formation of a hydrogen bond with Asn243; (3) substitution by hydrophobic groups at the 9-position of a purine enhances binding through interaction with hydrophobic region in the ribose-binding site; (4) acyclovir diphosphate is a multisubstrate inhibitor in which the acyclic spacer between N(9) of the purine and the phosphate is near optimal length to accommodate the two binding sites. Based on these results, a number of starting compounds were proposed that incorporated these and other features predicted to enhance inhibitor binding. 9-substituted 9-deaza purine analogs were selected as the first series of PNP inhibitors for synthesis. The first 9-deazaguanine derivatives synthesized, such as 9-benzyl-9-deazaguanine, were three to six times more potent than the most potent known inhibitor, 8-amino-9-(2-thienyl-methyl)guanine. Crystallographic data showed (Fig. 5 ) that the phenyl ring of the 9-benzyl compound tended to optimize its interactions with Phe159 and Phe200, resulting in the classic 'herringbone' arrangement reported in a variety of aromatic systems (Burley & Petsko, 1985) . In some cases, ring substitution resulted in displacement of the molecule centroid; however, the ring tilt relative to Phe159 and Phe200 remained relatively constant. The optimum spacer between the purine base and the aromatic substituent appears to be a single methylene group.
Asn 243
Asn 243 Both 8-aminoguanine analogs and 9-deazaguanine analogs are good inhibitors of PNP. However, introduction of an 8-amino group into the 9-deazaguanine derivatives resulted in decreased potency (Table 1) . To understand this poor binding, we undertook crystallographic analysis of PNP complexes with four compounds having the 9-thienyl substituent attached to guanine (G), 8-aminoguanine (8AG), 9-deazaguanine (DG) and 8-amino-9-deazaguanine (8ADG). The results of this analysis are summarized in Fig. 6 . These data show one mode of binding for compounds that accept a hydrogen bond from Asn243 at N7 (G and 8AG) and another for compounds that donate hydrogen from N7 to Asn243 (DG and 8ADG). The 8-aminoguanine analogs (8AG) make use of the Thr242 side chain to form an additional hydrogen bond which causes an improvement in binding affinity. In the 9-deazaguanine series, where N7 has an attached H atom, Asn243 undergoes a shift that is seen in difference Fourier maps. This shift is probably caused by the formation of the N(7)--H...0(243) hydrogen bond. At the same time, a concomitant shift by Thr242 prevents it from hydrogen bonding to the 8-amino group of the 9-deazaguanine (8ADG). Furthermore, the overall conformational change causes the methyl group of Thr242 to move towards the 8-amino group, thereby generating a hydrophobic environment for the 8-amino group and causing a decrease in binding affinity. This observation, confirmed with other 9-deazaguanine analogs, led us to focus on changes that would have more favourable interactions with the other two subsites.
Inhibitors with cycloaliphatic substituents at N9 of deazaguanine were also as potent as the aromatic analogs. The cycloaliphatic substituents occupied the same general volume as the aromatic groups (Fig. 7) . As with the aromatic series, the optimum spacer between the 9-deazaguanine and the hydrophobic substituent is one C atom. X-ray analysis of the PNP complexes of 9cyclohexyl-9-deazaguanine, a relatively poor inhibitor, and the complex of 9-cyclohexylmethyl-9-deazaguanine showed the surprising result that the two cyclohexyl groups occupy approximately the same general space in the active site and the 9-deazapurine is pulled out of its optimal position in the purine-binding pocket (Fig. 8) .
To take full advantage of the binding properties of the PNP active site, it is necessary to design compounds that interact optimally not only with the purine and hydrophobic binding sites but also with the phosphatebinding site (either directly or via electrostatic interactions). Starting with a model of the 9-benzyl-9deazaguanine-PNP complex, we concluded that two of the positions on the 9-benzyl group, namely the 2position of the phenyl ring and one of the benzylic sites, appeared to be oriented so that a group attached to either one of these positions could interact favourably with the phosphate-binding site. The first compound that was made in this series, 9-[2-(3-phosphonopropoxy)- Fig. 8. End view (left) and side view (right) comparison of the binding of 9-cyclohexyl-9-deazaguanine with that of 9-cyclohexylmethyl-9deazaguanine. The two cyclohexyl groups occupy approximately the same space in the active site, pulling the 9-deazaguanine moiety out of its optimal binding position in the purine-binding site.
--0 O- Fig. 9 . Comparison of the binding of 9-benzyl-9-deazaguanine (blue) with that of 9-[2-(3-phosphonopropoxy)benzyl]guanine (green) and 9-[2-(1-phosphonoethyi)benzyi]guanine (red). benzyl]guanine, turned out to be a poor PNP inhibitor. Subsequent crystallographic analysis revealed that the plane of the aromatic ring has rotated approximately 90 ° from its optimum position in the hydrophobic pocket (Fig. 9 ). This reorientafion of the ring is presumably necessary to accommodate the long spacer ( length) between the phenyl ring and the phosphonate group. A compound with a two-carbon spacer was a much better PNP inhibitor; however, it was clear from Xray analysis that the aromatic ring was still not able to form an ideal 'herringbone' packing interaction. Alternatively, compounds were modeled in which the spacer to the phosphate-binding site branched from the benzylic C atom, thus placing no restrictions on the tilt of the aromatic ring. Modeling studies of the 9-benzyl-9deazaguanine-PNP complex indicated that of the two This compound was resolved into its (S) and (R) isomers. As predicted, the (S)-acid was 30-fold more potent inhibitor of PNP than the (R) isomer and is the most potent membrane-permeable PNP inhibitor reported to date. X-ray crystallographic analysis of the complexes revealed that the (S)-acid was oriented properly for optimal interactions with all the three subsites (Fig. 10) , whereas the (R)-acid was not (Fig. 11) .
Crystallographic analysis of a number of inhibitor-PNP complexes revealed variations in the binding of the inhibitors in the enzyme active site. These differences appear to be the result of close contacts between the inhibitor and the ion in the phosphate-binding site. A sulfate ion occupies the phosphate site in PNP crystals as they are grown from ammonium sulfate solution. These inhibitors were more potent when the binding was measured in 1 mM phosphate solution than in 50mM phosphate (Table 2 ). Kinetic studies showed that these inhibitors are competitive not only with inosine but also with phosphate which is in keeping with the above observation.
This structure-based inhibitor design approach led to a number of inhibitors, which were more than 100 times more potent than any membrane-permeable inhibitor available at the start of this project. During the two and half years of this project, about 60 active compounds were synthesized. This is a remarkably small number compared with the extensive synthesis programmes that are generally involved in drug discovery by trial-anderror techniques. The large number of active compounds and the enhancement of inhibitor potency stand as proof that crystallographic and modeling techniques are now capable of playing a critical role in the rapid discovery of novel therapeutic agents.
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